Alliance Potential: Becoming the Target Choice in Big Pharma's Portfolio

Being chosen as a partner by big pharma is an accomplishment. Yet it doesn’t ensure alliance success, nor does simply having great science. In this paper, Oaklin’s Nick Palmer describes the key behaviours needed to ensure your partnership goes the distance.

Read Alliance Potential here.